skip to Main Content

Larotrectinib Efficacy Withstands Various NTRK Gene Fusions in Non-Primary CNS TRK Fusion+ Cancer

Newsfeed image, light gray text on dark gray background
Patients with NTRK fusions demonstrate a significant increase in survival and quality-of-life when treated with NTRK inhibitors, according to Marc Ladanyi, MD.

 

Larotectinib (Vitrakvi) is 1 such inhibitor that is FDA approved option for adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.        Read more . . . 


Back To Top